Catalog No.: PC-44643Not For Human Use, Lab Use Only.
HJC0350 is a potent and specific EPAC2 antagonist with IC50 of 0.3 uM for competing with 8-NBD-cAMP in binding EPAC2, about 133-fold more potent than cAMP.
HJC0350 is a potent and specific EPAC2 antagonist with IC50 of 0.3 uM for competing with 8-NBD-cAMP in binding EPAC2, about 133-fold more potent than cAMP.
HJC0350 exhibits no inhibition of EPAC1-mediated Rap1-GDP exchange activity at 25 uM.
HJC0350 selectively blocks cAMP-induced EPAC2 activation but does not inhibit cAMP-mediated PKA activation, fully blocks the 007-AM induced decrease of FRET in HEK293/EPAC2-FL cells at 10 uM.
